ArticleAbdominal radiology (New York)2026
CT imaging findings following treatment with combination SBRT and chemotherapy versus stand-alone chemotherapy for locally advanced pancreatic adenocarcinoma.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate imaging findings of patients with locally advanced pancreatic cancer (LAPC) following treatment with combination stereotactic body radiotherapy (SBRT) and chemotherapy versus stand-alone chemotherapy.
methodsThis retrospective study included patients with LAPC who received combination SBRT/chemotherapy versus those that received stand-alone chemotherapy from 2005 to 2018. Comparisons were made pre-treatment and at four standardized post-treatment intervals (1 month, 3-6 months, 7-12 months, greater than 12 months) in patients without disease progression. Imaging variables included degree of vascular involvement graded on a standardized scale and peripancreatic fat stranding. A p-value < 0.05 was considered significant.
resultsA total of 96 patients were included, 64 patients (37 men; mean age, 68 ± 11 years) treated with SBRT/chemotherapy and 32 patients (17 men; mean age, 69 ± 10 years) treated with stand-alone chemotherapy. Increased vascular involvement over time in the absence of disease progression was significantly higher in the SBRT/chemotherapy group (17%) versus the stand-alone chemotherapy group (9%), p = 0.004 (95% CI 2-12%). Peripancreatic fat stranding increased over time in the SBRT/chemotherapy group being present in 29/64 (45%) patients on the pre-treatment computed tomography (CT) versus 55/64 (86%) patients on the last recorded CT, p < 0.001 (McNemar OR = 14, 95% CI 3.3-58.8). No significant change in peripancreatic fat stranding over time was noted in the stand-alone chemotherapy group being present in 9/32 (28%) patients on the pre-treatment CT and 7/32 (22%) patients on the last imaging recorded, p = 0.45 (McNemar OR = 2, 95% CI 0.4-10.9).
conclusionsIncreased vascular involvement and peripancreatic fat stranding over time in LAPC patients treated with combination SBRT/chemotherapy should be a potential anticipated treatment-related effect, not necessarily indicating disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.